Recruiting
Phase 2

Trametinib

Sponsor:

Cook Children's Health Care System

Code:

NCT06582745

Conditions

Langerhans Cell Histiocytosis

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

Trametinib

Study Details

Brief summary:

The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.

Conditions

Langerhans Cell Histiocytosis

Study ID

NCT06582745

Start date

Jun 24, 2024

Status verified date

Apr, 2026

Completion date

Dec, 2039

Anticipated

Primary completion date

Jun, 2039

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis/disease status:

  • Patients with newly diagnosed Langerhans cell histiocytosis (LCH) OR
  • Patients with relapsed or refractory disease OR
  • Patients with newly diagnosed or relapsed/refractory disease who are receiving the liquid formula of trametinib OR
  • Patients who have been receiving trametinib as a treatment for LCH since January 1, 2020 may be included in the observational chart review to track long-term follow-up. Eligibility for chart review cohort will include receiving trametinib as treatment.
  • Diagnosis confirmed with biopsy prior to start of treatment
  • Patient must have adequate cardiac function evident through Echocardiogram (ECHO) and Electrocardiogram (EKG) within 30 days of starting treatment.

  • Shortening fraction of ≥ 27% by echocardiogram or
  • Ejection fraction of ≥ 50% by gated radionuclide study
  • QTC < 480 msec
  • Performance status: Patients must have a performance status corresponding to ECOG scores of 0, 1, or 2. Use Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥50% for patients ≤16 years of age.
  • Adequate organ and marrow function as defined below:

  • Absolute Neutrophil count ≥ 1,500/μL
  • Platelets ≥ 100x103/μL
  • Total bilirubin ≤ 1.5X ULN for age
  • AST/ALT ≤ 2.5 X ULN for age
  • Serum creatinine based on age/gender
  • Hemoglobin ≥ 8 g/dL

  • Patients with bone marrow disease must have hemoglobin ≥ 8 g/dL with transfusion support allowed
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after the last dose. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria:

  • Patients diagnosed with Low-Risk True Skin Only or a Single Bone lesion that does not require treatment and will only be observed will not be eligible, with the exception of CNS-risk lesions/special site disease or functionally critical lesions:

  • CNS-risk/special site includes: Sphenoid, Mastoid, Orbital, zygomatic, ethmoid, maxillary, or temporal bones, the cranial fossa, pituitary gland or neurodegenerative disease, odontoid peg, vertebral lesion with intraspinal soft tissue extension
  • Functionally critical: A single lesion not described above which may cause "functionally critical anatomic abnormality" wherein attempts at local therapy would cause unacceptable morbidity. This can be at the discretion of the Principal Investigator.
  • Patients whose genetic testing reveals a class 3 MAP2K1 mutation:

  • I103\_K104del
  • E102\_I103del
  • L98\_K104delinsQ
  • L98\_I103del
  • I99\_K104del
  • Patients who present with jaundice at diagnosis.
  • Patients who are pregnant or breastfeeding are not eligible. Women of childbearing potential must receive a negative pregnancy test within 14 days of starting treatment or the patient will not be eligible.

  • Patients who are allergic to trametinib
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of patient or parent/legally authorized representative to give written informed consent.

Study Design

Enrollment

75 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Prospective Treatment

Trametinib will be administered in 28-day cycles, given once daily or adjusted as per clinical judgment of the treating physician, with a maximum dosage of 2mg daily. Patients will be followed for 4 years after receiving treatment for two years. Patients may continue on the same treatment beyond two years if they and their treating physicians agree to do so in the best interest of the patient.

no intervention: Observation Only

Patients who have been receiving trametinib as a treatment for LCH since January 1, 2020 may be included in an observational chart review to track long-term follow-up.

Interventions

Trametinib

Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.

Primary outcome measure

  • Time to Progression (TTP) [ Time Frame: Up to six years ]
  • Progression-free Survival (PFS) [ Time Frame: Up to six years ]
  • Overall Survival (OS) [ Time Frame: Up to six years ]

Central Contacts and Locations

Central contacts

Megan Gibbs, BSN, RN

(682) 885-2116megan.gibbs@cookchildrens.org

Angelica Gonzalez, PhD

(682) 3033120angelica.gonzalez@cookchildrens.org

Locations

Cook Children's Health Care System

Recruiting

Fort Worth, Texas, United States, 76104

Contacts

Megan Gibbs, BSN, RN

682-885-2116Megan.Gibbs@cookchildrens.org

Principal Investigator:

Anish Ray, MD

More Information

Sponsor

Cook Children's Health Care System

Last update posted

Apr 7, 2026

Last verified

Apr, 2026

Keywords

  • LCH
  • MEK inhibitor
  • Targeted therapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Cook Children's Health Care System on 2026-04-07.